2024-03-07T17:25:20-06:00 2022-06-30 FORVIS LLP 1155 Avenue of the Americas 1200 New York NY 10036 990 2021-07-01 330841281 Pancreatic Cancer Action Network Inc % SUZANNE NEUMAN PANC 3107250025 1500 Rosecrans Avenue Suite 200 Manhattan Beach CA 90266 Anat Kendal CFO 5624351191 2024-01-15 true Anat Kendal 999009999 Aaron Shapiro P01333816 2128674000 2024-01-15 2021 2023-04-26 12:10:37Z X Julie Fleshman 1500 Rosecrans Avenue Manhattan Beach CA 90266 63700599 false X www.pancan.org X 1999 CA TO ADVANCE RESEARCH, SUPPORT PATIENTS, AND CREATE HOPE FOR PEOPLE WHO HAVE PANCREATIC CANCER. 14 13 191 2400 0 36292699 45401251 7330463 7241610 1457324 1332466 -227948 -3281201 44852538 50694126 3229138 10191634 0 0 18772145 22161066 0 0 5231425 18885336 22179705 40886619 54532405 3965919 -3838279 68087532 65833440 18599627 26967968 49487905 38865472 X OUR MISSION IS TO TAKE BOLD ACTION TO IMPROVE THE LIVES OF EVERYONE IMPACTED BY PANCREATIC CANCER BY ADVANCING SCIENTIFIC RESEARCH, BUILDING COMMUNITY, SHARING KNOWLEDGE, AND ADVOCATING FOR PATIENTS. false false 26824334 10191634 7241610 RESEARCH - PANCAN FUNDS GROUNDBREAKING RESEARCH INITIATIVES THAT WILL TRANSFORM THE WAY PANCREATIC CANCER IS DETECTED AND TREATED. WE FUND RESEARCH GRANTS TO INDIVIDUAL INVESTIGATORS AND LARGE-SCALE, MULTI-INSTITUTIONAL CLINICAL PROJECTS THAT ARE FOCUSED ON ADVANCING NEW TREATMENTS AND EARLY DETECTION FOR PANCREATIC CANCER. WE INVESTED ARECORD $25 MILLION IN RESEARCH IN FISCAL YEAR 2022. RESEARCH FUNDING THAT SUPPORTED IMPORTANT RESEARCH PROJECTS AT INSTITUTIONS ACROSS THE COUNTRY, AND PANCAN'S PRECISION PROMISE ADAPTIVE CLINICAL TRIAL, EARLY DETECTION INITIATIVE, KNOW YOUR TUMOR PRECISION MEDICINE SERVICE, AND PATIENT REGISTRY. SINCE 2003, PANCAN HAS AWARDED 234 RESEARCH GRANTS TO 213 SCIENTISTS AT 79 INSTITUTIONS. PANCAN'S CUMULATIVE RESEARCH INVESTMENT IS NOW MORE THAN $174 MILLION, MAKING A SIGNIFICANT IMPACT GRANTS TO 213 SCIENTISTS AT 79 INSTITUTIONS. PANCAN'S CUMULATIVE RESEARCH INVESTMENT IS NOW MORE THAN $174 MILLION, MAKING A SIGNIFICANT IMPACT on the diagnosis, treatment and care of today's patients and those who will be diagnosed in the future. 6981104 COMMUNITY ENGAGEMENT - 59 VOLUNTEER-LED AFFILIATES WITH OVER 2,400 VOLUNTEERS RAISE AWARENESS OF PANCAN AND THE DISEASE AND EDUCATE THEIR COMMUNITIES ABOUT PANCREATIC CANCER. VOLUNTEERS HOSTED 60 PURPLESTRIDE EVENTS ACROSS THE COUNTRY THIS PAST YEAR, OVER 56,000 PARTICIPANTS REGISTERED SUPPORTING SURVIVORS, FAMILIES AND FRIENDS, AS WELL AS PROVIDING EDUCATIONAL INFORMATION AT THE EVENTS. WE ARE ALSO A FOUNDING MEMBER OF THE WORLD PANCREATIC CANCER COALITION, COMPRISING MORE THAN 90 PANCREATIC CANCER PATIENT ADVOCACY GROUPS FROM OVER 30 COUNTRIES AND SIX CONTINENTS. THE COALITION HOSTS WORLD PANCREATIC CANCER DAY EVERY NOVEMBER TO RAISE GLOBAL AWARENESS OF THE DISEASE. PURPLESTRIDE PARTICIPANTS RAISED OVER $12.5 MILLION. 4635006 PATIENT SERVICES - PROVIDES FREE, PERSONALIZED INFORMATION AND RESOURCES ABOUT PANCREATIC CANCER, TREATMENT OPTIONS, CLINICAL TRIALS, DIET AND NUTRITION, SPECIALISTS AND SUPPORT RESOURCES TO HELP PATIENTS, CAREGIVERS AND HEALTHCARE PROVIDERS. WE HAVE THE LARGEST, MOST UP-TO-DATE CLINICAL TRIALS DATABASE IN THE COUNTRY AND PROVIDE CONSTITUTENTS WITH PERSONALIZED SEARCHES SO THAT THEY UNDERSTAND ALL OF THEIR TREATMENT OPTIONS. OUR EXPERT PATIENT SERVICES CASE MANAGERS SHARE MORE RESOURCES AND SPEAK WITH MORE PANCREATIC CANCER PATIENTS THAN ANY OTHER ORGANIZATION IN THE WORLD. LAST YEAR ALONE, WE HAD NEARLY 48,000 INTERACTIONS WITH PANCREATIC CANCER PATIENTS AND FAMILIES. 1403585 39844029 true true false true false false false false false false true false false false true true true false false false false false false false true false false true false true false false false false false false false false true false false false false false false false true 53 0 true 191 true false false false false false false true 1 false false false false false X 14 13 false false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X SUZANNE NEUMAN 3107250025 1500 ROSECRANS AVENUE 200 MANHATTAN BEACH CA 90266 Julie Fleshman PRESIDENT & CEO/DIRECTOR 50.0 0.0 X X 678051 0 37837 Sudheer Doss CHIEF BUSINESS OFFICER 50.0 0.0 X 425965 0 24357 Anne-Marie Duliege CHIEF MED. OFFICER THRU 3/2022 50.0 0.0 X 392840 0 20924 LYNN MATRISIAN CHIEF SCIENCE OFFICER 50.0 0.0 X 362476 0 22886 LORI STEVENS CHIEF DEVELOPMENT OFFICER 50.0 0.0 X 349620 0 24475 THOMAS CROAL CFO THRU 6/2021 50.0 0.0 X 337895 0 17872 EDWINA MOSSETT CHIEF PEOPLE OFFICER 50.0 0.0 X 331080 0 19222 JODI LIPE CHIEF MKTG & COMM. OFFICER 50.0 0.0 X 318614 0 24893 RICHARD LEONARD NATIONAL DIR., LEADERSHIP GIVI 50.0 0.0 X 267046 0 19306 HILARIE KOPLOW-MC ADAMS CHAIRMAN 2.0 0.0 X X 0 0 0 KAREN YOUNG CPA VICE CHAIRMAN 2.0 0.0 X X 0 0 0 MARCO ARGENTI BOARD MEMBER 2.0 0.0 X 0 0 0 PETER CASHION BOARD MEMBER 2.0 0.0 X 0 0 0 DENNIS CRONIN BOARD MEMBER 2.0 0.0 X 0 0 0 BARBARA J KENNER PHD BOARD MEMBER 2.0 0.0 X 0 0 0 MICHAEL AG KORENGOLD BOARD MEMBER 2.0 0.0 X 0 0 0 JASON KUHN BOARD MEMBER 2.0 0.0 X 0 0 0 LISA KULOK BOARD MEMBER 2.0 0.0 X 0 0 0 CRAIG A ROGERSON BOARD MEMBER 2.0 0.0 X 0 0 0 NANCY STAGLIANO PHD BOARD MEMBER 2.0 0.0 X 0 0 0 KARYN A TEMPLE BOARD MEMBER AS OF 7/2021 2.0 0.0 X 0 0 0 ROD WILLIAMS MBA BOARD MEMBER 2.0 0.0 X 0 0 0 ANAT KENDAL CFO AS OF 1/2022 50.0 0.0 X 0 0 0 3463587 0 211772 53 true true false Media Storm LLC PO Box 6411 BRATTLEBORO VT 05302 ADVERTISING 567913 Berry Consultants LLC 3345 Bee Caves Rd Suite 201 AUSTIN TX 78746 CONSULTING SERVICES 468000 Motion 5015 Arden Avenue EDINA MN 55424 VIDEO PRODUCTION 302135 Schaner Lubitz PLLC 4550 Montgomery Ave Suite 1100 N BETHESDA MD 20814 LEGAL SERVICES 168255 Cavarocchi Ruscio Dennis Associates 600 Maryland Avenue SW Suite 220 Ea WASHINGTON DC 20024 CONSULTING SERVICES 144007 6 176511 15838155 1950000 27436585 666964 45401251 CLINICAL RESEARCH CONTRACTS 541700 7241610 7241610 7241610 1176978 1176978 0 0 0 0 0 9815087 9659599 155488 155488 155488 0 15838155 3316146 -3316146 -3316146 0 0 0 65673 30728 34945 34945 0 50694126 7276555 -1983680 10191634 10191634 0 0 0 1727147 1029188 423106 274853 0 17244287 10271171 4230025 2743091 583622 350477 139601 93544 1329044 798118 317904 213022 1276966 766844 305447 204675 0 96341 56703 39638 35386 20827 14559 314265 314265 0 188702 188702 15048167 12872067 1249873 926227 1388838 1293202 72282 23354 1553075 275983 1103420 173672 1203107 224917 795536 182654 0 1064188 642471 278361 143356 437961 294427 114746 28788 0 0 0 0 322975 269246 33005 20724 245888 101083 144805 DONOR AND AFFILIATE AGREEMENT 280812 71406 5941 203465 54532405 39844029 9456951 5231425 78355 7737919 21067523 13890504 11854561 8249392 1613670 4413423 0 0 0 0 0 0 44260 40327 1007398 829383 5776493 5274978 689326 501515 31568624 29948473 0 0 0 0 0 0 163815 222504 68087532 65833440 7169708 11973537 7618348 12349632 971345 1869944 0 0 0 0 0 0 0 0 1950000 0 890226 774855 18599627 26967968 X 40871033 31481468 8616872 7384004 49487905 38865472 68087532 65833440 -3838279 -4758232 -2025922 X false true X true false X 53040826 41998701 35529596 36292699 45401251 212263073 0 0 53040826 41998701 35529596 36292699 45401251 212263073 24043240 188219833 553922 887064 907982 697700 1176978 4223646 0 14854 450 20400 35704 216522423 16767479 0.86929 0.81560 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 120132 194133 314265 54218140 54532405 1000000 250000 1000000 1000000 1000000 1000000 4000000 6000000 232229 98429 268448 314265 913371 250000 250000 250000 250000 1000000 1500000 59150 4939 109672 120132 293893 SCHEDULE C, PART II-A PANCAN ENGAGES IN DEVELOPING REPORT LANGUAGE FOR APPROPRIATIONS BILLS; DEVELOPING ALERTS TO OUR MEMBERS REGARDING SPECIFIC LEGISLATION; PREPARING FOR AND ATTENDING VISITS ON CAPITAL HILL BY OUR MEMBERS AND THE PUBLIC DURING ADVOCACY DAYS BOTH IN PERSON AND VIRTUALLY; GIVING UNINVITED AND INVITED TESTIMONY OR WRITTEN RESPONSES DURING LEGISLATIVE HEARINGS; AND DEVELOPING GENERAL EDUCATION MESSAGES THROUGH MEDIA CAMPAIGNS THAT DO OR DO NOT INCLUDE A CALL FOR ACTION. 890471 833786 56685 1507324 1223572 283752 3378698 3217620 161078 501515 0 LEASE LIABILITY & OTHER INSTALLMENT OBLIGATIONS 774855 774855 45747192 -4758232 -4758232 50505424 188702 188702 50694126 54343703 54343703 188702 188702 54532405 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND APPLICABLE STATE LAWS. THE ORGANIZATION RECOGNIZES THE FINANCIAL STATEMENT BENEFIT OF TAX POSITIONS, SUCH AS FILING STATUS OF TAX-EXEMPT, ONLY AFTER DETERMINING THAT THE RELEVANT TAX AUTHORITY WOULD MORE LIKELY THAN NOT SUSTAIN THE POSITION FOLLOWING AN AUDIT. THE ORGANIZATION HAD NO MATERIAL NET UNRELATED BUSINESS INCOME REQUIRING RECOGNITION FOR THE YEARS ENDED JUNE 30, 2022 AND 2021. THE ORGANIZATION IS SUBJECT TO POTENTIAL INCOME TAX AUDITS ON OPEN TAX YEARS BY ANY TAXING JURISDICTION IN WHICH IT OPERATES. THE STATUTE OF LIMITATIONS FOR FEDERAL AND CALIFORNIA STATE PURPOSES IS GENERALLY THREE AND FOUR YEARS, RESPECTIVELY. PURPLESTRIDE 15838155 15838155 5474 1391783 5325 154886 1758678 0 15838155 15838155 5474 1391783 5325 154886 1758678 3316146 -3316146 SCHEDULE G, PART I, LINE 3: THE ORGANIZATION IS REGISTERED TO FUNDRAISE IN EVERY STATE. IN FISCAL YEAR 2022, THE PROPER STATE REGISTRATION FORMS WERE FILED. true UNIVERSITY OF PITTSBURGH 116 ATWOOD STREET SUITE 201 PITTSBURGH PA 15260 250965591 501(C)(3) 250000 FUND RESEARCH CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 501(C)(3) 100000 FUND RESEARCH COLUMBIA UNIVERSITY MEDICAL CENTER 154 HAVEN AVENUE 2ND FL NEW YORK NY 10032 135598093 501(C)(3) 500000 FUND RESEARCH DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 300000 FUND RESEARCH FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501(c)(3) 500000 FUND RESEARCH GEORGETOWN UNIVERSITY 37TH AND O STREETS NW WASHINGTON DC 20057 530196603 501(C)(3) 250000 FUND RESEARCH LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 250000 FUND RESEARCH JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE 411 CAROLINE STREET BALTIMORE MD 21231 520595110 501(C)(3) 250000 FUND RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON SC 29425 576000722 250000 FUND RESEARCH PURDUE UNIVERSITY 201 S UNIVERSITY STREET WEST LAFAYETTE IN 47907 356002041 501(C)(3) 250000 FUND RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 500 SOUTH STATE STREET ANN ARBOR MI 48109 386006309 501(C)(3) 275000 FUND RESEARCH ROSWELL PARK COMPREHENSIVE CANCER CENTER ELM AND CARLTON STREETS BUFFALO NY 14263 141402155 501(C)(3) 250000 FUND RESEARCH THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 300000 FUND RESEARCH THE DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 300000 FUND RESEARCH THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET P-221 PHILADELPHIA PA 19104 231352685 501(C)(3) 565000 FUND RESEARCH THE WISTAR INSTITUTE 3601 SPRUCE STREET PHILADELPHIA PA 19104 236434390 501(C)(3) 250000 FUND RESEARCH UNIVERSITY OF CINNCINATI 51 GOODMAN DRIVE SUITE 530 CINCINNATI OH 45221 316000989 501(C)(3) 250000 FUND RESEARCH UNIVERSITY OF MIAMI 1320 S DIXIE HIGHWAY GABLES ONE TO CORAL GABLES FL 33145 590624458 501(C)(3) 250000 FUND RESEARCH UNIVERSITY OF NORTH CAROLINA 104 AIRPORT DRIVE SUITE 2200 CHAPEL HILL NC 27599 566001393 501(C)(3) 340000 FUND RESEARCH UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 230000 FUND RESEARCH VERASTEM ONCOLOGY 117 KENDRICK STREET SUITE 500 NEEDHAM MA 02494 273269467 4300000 FUND RESEARCH WASHINGTON UNIVERSITY 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501(C)(3) 300000 FUND RESEARCH 19 3 PART I, LINE 2: THE PANCREATIC CANCER ACTION NETWORK ADMINISTERS ITS RESEARCH GRANTS PROGRAM IN HOUSE. THE AMOUNT OF THE GRANTS AND ELIGIBILITY CRITERIA ARE DETERMINED BY THE ORGANIZATION'S SCIENTIFIC LEADERSHIP IN ADVANCE OF PUBLIC NOTIFICATION OF GRANT AVAILABILITY. GRANTS ARE SELECTED BY SCIENTIFIC REVIEW PERFORMED BY A PANEL OF PEER EXPERTS. ALL GRANT AMOUNTS, ELIGIBILITY CRITERIA, AND REVIEW PROCESSES ARE DOCUMENTED ANNUALLY IN THE INDIVIDUAL GRANT APPLICATION PROCEDURE DOCUMENTS. GRANT AMOUNTS, GRANT RESTRICTIONS (INCLUDING USE OF FUNDS) AND REPORTING PROCESSES ARE SPECIFIED IN THE GRANT AGREEMENT BETWEEN THE GRANTEE'S INSTITUTION AND THE ORGANIZATION. PROGRESS REPORTS ARE REQUIRED FOR ALL GRANTS AWARDED. THESE PROGRESS REPORTS ARE COLLECTED AND REVIEWED BY THE GRANTS ASSOCIATE DIRECTOR AND DOCUMENTED IN THE INDIVIDUAL GRANT POST AWARD FILES. PROGRESS REPORTS INCLUDE A DESCRIPTION OF THE RESEARCH WORK ACCOMPLISHED, FUNDS USED, LESSONS LEARNED AND OTHER OUTCOMES. FINAL REPORTS ARE DUE WITHIN TWO MONTHS OF THE COMPLETION OF THE GRANT PERIOD AND MUST ACCOUNT FOR THE ENTIRE GRANT AMOUNT. PROGRAM STAFF COMMUNICATE DIRECTLY WITH GRANT RECIPIENTS TO RESOLVE QUESTIONS OR DISCREPANCIES. THIS PROCESS IS DOCUMENTED IN THE GRANT AGREEMENT BETWEEN THE GRANTEE INSTITUTION AND THE ORGANIZATION. THE PANCREATIC CANCER ACTION NETWORK HAS ESTABLISHED OTHER GRANT AGREEMENTS TO FUND SCIENTIFIC INITIATIVES IN CLINICAL TRIALS RESEARCH AND EARLY DETECTION OF PANCREATIC CANCER. X X X X X X true true false true false false false false false Julie Fleshman PRESIDENT & CEO/DIRECTOR 474551 172000 31500 11600 26237 715888 Sudheer Doss CHIEF BUSINESS OFFICER 335965 90000 11600 12757 450322 Anne-Marie Duliege CHIEF MED. OFFICER THRU 3/2022 360895 31945 5400 15524 413764 LYNN MATRISIAN CHIEF SCIENCE OFFICER 307476 55000 11600 11286 385362 LORI STEVENS CHIEF DEVELOPMENT OFFICER 269620 80000 11308 13167 374095 THOMAS CROAL CFO THRU 6/2021 179895 55000 103000 5665 12207 355767 EDWINA MOSSETT CHIEF PEOPLE OFFICER 276080 55000 11600 7622 350302 JODI LIPE CHIEF MKTG & COMM. OFFICER 263614 55000 11600 13293 343507 RICHARD LEONARD NATIONAL DIR., LEADERSHIP GIVI 232046 35000 9494 9812 286352 PART I, LINES 4A-B: LINE 4A: THE FOLLOWING INDIVIDUAL RECEIVED A SEVERANCE PAYMENT DURING FISCAL YEAR ENDED JUNE 30, 2022: THOMAS CROAL $103,000. LINE 4B: THE FOLLOWING INDIVIDUAL PARTICIPATES IN A NON-QUALIFIED TAXABLE RETIREMENT PLAN OF THE ORGANIZATION. THE AMOUNT SHOWN REPRESENTS THE ORGANIZATION'S EMPLOYER CONTRIBUTION TO THE PLAN FOR THE YEAR ENDED JUNE 30, 2022: JULIE FLESHMAN $19,500. PART I, LINE 5: THE PERFORMANCE INCENTIVE PLAN REWARDS OUR VALUED TEAM MEMBERS IF CERTAIN REVENUE GOALS ARE REACHED. X 77 606066 FMV X 1 45000 selling price X 19 13858 fmv X GIFT CARDS 9 1820 FMV X SUPPLIES 1 220 FMV 1 false true false SCHEDULE M, PART I, COLUMN (B): THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES: GOVERNMENT AFFAIRS AND ADVOCACY - WE DRIVE LEGISLATIVE SUPPORT FOR INCREASED FEDERAL RESEARCH FUNDING FOR PANCREATIC CANCER. OUR GRASSROOTS ADVOCACY EFFORTS LED TO THE PASSAGE OF THE RECALCITRANT CANCER RESEARCH ACT, INCREASED RESEARCH DOLLARS FOR PANCREATIC CANCER AT THE NATIONAL CANCER INSTITUTE, AND LED TO A NEW PANCREATIC CANCER RESEARCH PROGRAM AT THE DEPARTMENT OF DEFENSE. SINCE OUR FOUNDING, FEDERAL RESEARCH FUNDING FOR PANCREATIC CANCER HAS INCREASED BY 900 PERCENT AND CONTINUES TO INCREASE EACH YEAR DUE TO OUR EFFORTS. FORM 990, PART VI, SECTION B, LINE 11B: THE ORGANIZATION'S AUDIT AND INVESTMENT COMMITTEE ("AIC") RECEIVES AND REVIEWS THE DRAFT OF THE FORM 990, INCLUDING SCHEDULES, PRIOR TO THE FILING OF THE RETURN. A MEETING OF THE AIC, INCLUDING THE PRESIDENT AND CEO, VP OF FINANCE, THE CFO, THE CONTROLLER, AND THE OUTSIDE CPA FIRM, IS THEN HELD TO REVIEW AND REVISE THE DRAFT OF THE FORM 990 AS NECESSARY. UPON APPROVAL OF THE DRAFT FORM 990 BY THE AIC, THE FINAL FORM 990, WITH CHANGES REFLECTED, IF ANY, IS E-MAILED TO THE ENTIRE BOARD OF DIRECTORS FOR REVIEW PRIOR TO FILING. UPON BOARD APPROVAL, THE FINAL FORM 990 IS FILED ELECTRONICALLY. FORM 990, PART VI, SECTION B, LINE 12C: THE BOARD OF DIRECTORS IS REQUIRED TO SUBMIT AN UPDATED CONFLICT OF INTEREST STATEMENT ANNUALLY. TO THE EXTENT THAT RELATIONSHIPS ARE IDENTIFIED VIA THESE STATEMENTS AND OTHER INFORMATION, THE INDIVIDUAL'S CONSTITUENT RECORD IS UPDATED TO INCLUDE THIS INFORMATION, FACILITATING PERIODIC QUERIES, AS NECESSARY. THE MEMBER WITH A CONFLICT MUST IDENTIFY THE CONFLICT AT ANY BOARD MEETING WHERE THE CONFLICT IS RELEVENT. THE MEMBER CANNOT BE PRESENT AT ANY PART OF THE MEETING WHERE THE RELEVENT TOPIC IS DISCUSSED OR VOTED ON. THE MEMBER CANNOT BE COUNTED FOR A QUORUM. FORM 990, PART VI, SECTION B, LINE 15: THE BOARD COMPENSATION COMMITTEE IS RESPONSIBLE FOR THE ANNUAL REVIEW AND APPROVAL OF THE COMPENSATION FOR TOP-LEVEL EXECUTIVE MANAGEMENT, OFFICERS, AND KEY EMPLOYEES. THE CHIEF PEOPLE OFFICER STAYS ABREAST OF INDUSTRY SALARY LEVELS AND ALERTS THE COMMITTEE TO ANY CHANGE IN SALARY LEVELS. INDEPENDENT PROFESSIONAL EXPERTS ARE CALLED UPON FOR HIGHER-LEVEL POSITIONS AND ASSIST IN ESTABLISHING EXECUTIVE SALARIES IN THE COMPETITIVE MARKETPLACE. SALARIES IN BOTH FOR-PROFIT AND NOT-FOR-PROFIT ORGANIZATIONS ARE EVALUATED IN ORDER TO ATTRACT THE MOST TALENTED PERSONNEL. INFORMATION IS GATHERED, ANALYZED AND REPORTED TO THE COMMITTEE PRIOR TO THEIR MEETINGS ON COMPENSATION WITH THE INTENT OF ENSURING THAT THE EXECUTIVE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE REVIEW INCLUDES INCENTIVE PLANS AND ALL FRINGE BENEFITS AS WELL AS BASE SALARY ARRANGEMENTS. THE BOARD ESTABLISHES THE CEO/PRESIDENT SALARY LEVEL DURING THE EXECUTIVE SESSION OF A CALLED BOARD MEETING. ONCE APPROVED, EXECUTIVE COMPENSATION PACKAGES ARE FORMALIZED IN WRITING AND, ONCE ACCEPTED BY THE EXECUTIVE, RETAINED IN THE PERSONNEL FILE(S). FORM 990, PART VI, SECTION C, LINE 19: THE ORGANIZATION HAS A FORMAL POLICY FOR PUBLIC DISCLOSURE AND INSPECTION OF DOCUMENTS. THE POLICY IS POSTED ON THE ORGANIZATION'S WEBSITE. FORM 990, PART VIII, LINE 1E, PPP LOAN FORGIVENESS: IN MARCH 2020, CONGRESS PASSED THE PAYCHECK PROTECTION PROGRAM (PPP), AUTHORIZING LOANS TO SMALL BUSINESSES FOR USE IN PAYING EMPLOYEES THAT THEY CONTINUE TO EMPLOY THROUGHOUT THE COVID-19 PANDEMIC AND FOR RENT, UTILITIES, AND INTEREST ON MORTGAGES. LOANS OBTAINED THROUGH THE PAYCHECK PROTECTION PROGRAM ARE ELIGIBLE TO BE FORGIVEN AS LONG AS THE PROCEEDS ARE USED FOR QUALIFYING PURPOSES AND CERTAIN OTHER CONDITIONS ARE MET. IN JUNE 2020, THE ORGANIZATION RECEIVED LOAN PROCEEDS IN THE AMOUNT OF $1,950,000 UNDER THE PPP. ON AUGUST 6, 2021, THE SMALL BUSINESS ADMINISTRATION APPROVED FORGIVENESS OF THE PPP LOAN IN FULL. THE ORGANIZATION RECOGNIZED FORGIVENESS OF THE PPP LOAN AS REVENUE DURING THE YEAR ENDED JUNE 30, 2022. FORM 990, Page 1, Box B THE RETURN IS BEING AMENDED DUE TO A RE-STATEMENT OF THE AUDITED FINANCIAL STATEMENTS. CHANGES HAVE BEEN MADE TO THE FOLLOWING SECTIONS: PART I, PART III, PART VII, PART VIII, PART IX, PART X, PART XI, SCHEDULE A, SCHEDULE C, SCHEDULE D, SCHEDULE G, AND SCHEDULE O. FORM 990 PART IX LINE 11G DESCRIPTION:OTHER FEES TOTAL FEES:15048167